摘要
目的:对多发性骨髓瘤患者予以不同剂量硼替佐米治疗,观察并分析患者的临床疗效差异性。方法:选择我院收治的78例多发性骨髓瘤患者作为临床观察对象,所有患者均予以硼替佐米治疗。将所有患者依据药物治疗的不同分为两组,对照组患者硼替佐米使用剂量为1.6mg/m^3,研究组患者硼替佐米使用剂量在1.0~1.3mg/m^3之间。比较并分析两组患者的不良反应发生情况以及治疗效果。结果:研究组患者治疗总有效率与对照组患者比较明显更高,P<0.05;研究组患者PLT减少、WBC减少、肝功能异常、贫血、周围神经病变以及腹部不适等不良反应总发生率与对照组患者比较明显更低,P<0.05。结论:在多发性骨髓瘤患者采用硼替佐米治疗具有一定疗效,但是不同用药剂量的临床疗效也具有一定差异性,1.0~1.3mg/m^3剂量硼替佐米疗效明显高于1.6mg/m^3剂量疗效,且安全性更高。
Objective:Patients with multiple myeloma were treated with different doses of bortezomib to observe and analyze the difference of clinical efficacy.Methods:78 patients with multiple myeloma admitted to our hospital were selected as clinical observation objects,and all patients were treated with bortezomib.All patients were divided into two groups according to different drug treatments.The dose of bortezomib in the control group was 1.6mg/m^3,and the dose of bortezomib in the research group was 1.0-1.3mg/m^3.The adverse reactions and therapeutic effects of the two groups were compared and analyzed.Results:The total effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05).The total incidence of PLT,WBC,abnormal liver function,anemia,peripheral neuropathy and abdominal discomfort in the study group was significantly lower than that in the control group(P<0.05).Conclusion:Bortezomib has certain efficacy in the treatment of multiple myeloma patients,but the clinical efficacy of different doses is also different.The efficacy of 1.0-1.3mg/m^3 of bortezomib is significantly higher than that of 1.6mg/m^3,and the safety is higher.
作者
杨瑞
YANG Rui(Yingtan People’s Hospital,Yingtan Jiangxi 335000,China)
出处
《药品评价》
CAS
2019年第24期32-32,34,共2页
Drug Evaluation
关键词
多发性骨髓瘤
硼替佐米
临床疗效
Multiple Myeloma
Bortezomib
Clinical Curative Effect
